Sorafenib - Small Molecule (ID:10008-104)

HMS LINCS ID: 10008-104
Name: Sorafenib
Alternative Names: BAY-439006
LINCS ID: LSM-1008
PubChem CID: 216239
ChEBI ID:
ChEMBL ID: 1336
Molecular Mass: 464.09
InChi: InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)
InChi Key: MLDQJTXFUGDVEO-UHFFFAOYSA-N
SMILES: CNC(=O)C1=NC=CC(=C1)OC2=CC=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F
Relevant Citations:
Comments:
Date Publicly Available:
Most Recent Update: 2016-04-04

Target Affinity:

(see Study 20000)
Target Affinity Spectrum Value HUGO Gene Name
1
(Kd <100 nM)
BRAF, CSF1R, DDR1, DDR2, EPHX2, FLT1, FLT3, FLT4, HIPK4, HTR2B, KDR, KIT, MAP3K19, MAP3K20, MAPK15, PDGFRA, PDGFRB, RAF1, RET, TIE1, TKT
2
(equivalent to 100 nM ≤ Kd < 1µM)
Abl1, ABL1, AIM1, AURKB, AURKC, CDK19, CDK7, CDK8, CDKL2, CDKL3, EPHA6, EPHB6, FPGT-TNNI3K, FRK, HIPK3, HTR2C, MAP2K5, MAP3K7, MAPK11, MAPK14, MKNK1, MKNK2, MUSK, NLK, NTRK3, Pdgfrb, PF3D7_0217500, STK10, TAOK2, TNNI3K
3
(equivalent to 1µM ≤ Kd < 10 µM)
ABL2, AURKA, AXL, CCND1, CDC7, CDK1, CDK14, CDK15, CDK17, CDK2, CDK3, CDK4, CDK5, CIT, CLK1, CSNK1A1, DYRK3, EEF2K, EPHA1, EPHA2, EPHA3, EPHA4, EPHA5, EPHA7, EPHA8, EPHB1, EPHB2, EPHB4, FGFR1, FGFR2, FGFR3, FGR, FLG, FYN, GRK5, HCK, HIPK1, HIPK2, HTR1A, HTR2A, HTR5A, HTR6, HTR7, JAK3, kdr, LCK, LIMK1, LIMK2, LYN, MAP4K1, MAP4K4, MAP4K5, MAPK12, MAPK13, MAPK9, MERTK, MYLK2, MYLK3, MYO3B, NEK4, NTRK1, NTRK2, PASK, PLK4, PRKCG, PRKCZ, RIPK2, RPS6KA6, SGK2, SLK, SRMS, STK33, STK36, TAOK1, TAOK3, TEK, TGFBR2, TNIK, TNK1, TSSK2, TTK
10
(confirmed non-binding)
(Click to show)

Datasets:

HMS Dataset ID Dataset Title HMS Dataset Type
20000
Target Affinity Spectrum (TAS) vectors for compounds in the HMS LINCS small molecule library.
Analysis
20268
Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates.
 Analysis
20269
Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 2 of 4: Calculated dose-response metrics.
Analysis
20270
Growth rate-corrected (GR) dose-response metric signatures across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 3 of 4: Median, upper quartile, and lower quartile GR metrics per perturbagen.
Analysis

Batch Information:

HMS LINCS Batch ID Provider Provider Batch ID
10008-104-3 LC Laboratories